keyword
MENU ▼
Read by QxMD icon Read
search

Betaferon

keyword
https://www.readbyqxmd.com/read/29521573/effect-of-hla-drb1-alleles-and-genetic-variants-on-the-development-of-neutralizing-antibodies-to-interferon-beta-in-the-beyond-and-benefit-trials
#1
Dorothea Buck, Till Fm Andlauer, Wilmar Igl, Eva-Maria Wicklein, Mark Mühlau, Frank Weber, Karl Köchert, Christoph Pohl, Barry Arnason, Giancarlo Comi, Stuart Cook, Massimo Filippi, Hans-Peter Hartung, Douglas Jeffery, Ludwig Kappos, Frederik Barkhof, Gilles Edan, Mark S Freedman, Xavier Montalbán, Bertram Müller-Myhsok, Bernhard Hemmer
BACKGROUND: Treatment of multiple sclerosis (MS) with interferon β can lead to the development of antibodies directed against interferon β that interfere with treatment efficacy. Several observational studies have proposed different HLA alleles and genetic variants associated with the development of antibodies against interferon β. OBJECTIVE: To validate the proposed genetic markers and to identify new markers. METHODS: Associations of genetic candidate markers with antibody presence and development were examined in a post hoc analysis in 941 patients treated with interferon β-1b in the Betaferon® Efficacy Yielding Outcomes of a New Dose (BEYOND) and BEtaseron® /BEtaferon® in Newly Emerging multiple sclerosis For Initial Treatment (BENEFIT) prospective phase III trials...
March 1, 2018: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/29318028/interferon-beta-1b-in-treatment-na%C3%A3-ve-paediatric-patients-with-relapsing-remitting-multiple-sclerosis-two-year-results-from-the-betapaedic-study
#2
Jutta Gärtner, Wolfgang Brück, Almuth Weddige, Hannah Hummel, Christiane Norenberg, Jörg-Peter Bugge
Background and objective: Study evaluating Betaferon(R)'s safety and tolerability in paediatric patients with multiple sclerosis (BETAPAEDIC) is a prospective, open-label observational multicentre study to assess the safety and effectiveness of interferon beta-1b in paediatric patients with relapsing-remitting multiple sclerosis. Methods: Treatment-naïve patients (12-16 years) scheduled to start interferon beta-1b were enrolled with follow-up visits every six months for two years...
October 2017: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://www.readbyqxmd.com/read/29049356/treatment-satisfaction-with-injectable-disease-modifying-therapies-in-patients-with-relapsing-remitting-multiple-sclerosis-the-stick-study
#3
Oscar Fernández, Eduardo Duran, Teresa Ayuso, Luis Hernández, Inmaculada Bonaventura, Mireia Forner
BACKGROUND: Treatment satisfaction in patients with relapsing-remitting multiple sclerosis (RRMS) may impact adherence and thus clinical outcomes. The objective of this study was to measure the satisfaction of patients with RRMS with injectable disease-modifying therapies (DMTs) and to evaluate the factors associated with treatment satisfaction. MATERIAL AND METHODS: In this observational retrospective study conducted in the neurology departments of 35 hospitals throughout Spain, demographic data, disease characteristics, and information on treatment with injectable DMTs were collected at a single scheduled visit...
2017: PloS One
https://www.readbyqxmd.com/read/28427690/factors-associated-with-adherence-to-disease-modifying-therapy-in-multiple-sclerosis-an-observational-survey-from-a-referral-center-in-lithuania
#4
Neringa Duchovskiene, Dalia Mickeviciene, Giedre Jurkeviciene, Birute Dirziuviene, Renata Balnyte
AIM OF THE STUDY: To investigate adherence to disease modifying therapy (DMT) in Lithuanian population of multiple sclerosis patients and factors associated to it. METHODS: Patients receiving one of the following DMT's: Interferon β 1a (Rebif) 44 micrograms three times a week subdermally (s/c) or Interferon β 1a (Avonex) 30 micrograms weekly intramuscularly (i/m), or Interferon β 1b (Betaferon, Extavia) 250 micrograms once in two days s/c, or Glatiramer acetate (Copaxone) 20mg daily s/c, were presented with a questionnaire inquiring their demographic and clinical characteristics and adherence to treatment profile, as well as HAD scale and SF-36 questionnaire...
April 2017: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/28170401/clinical-practice-of-analysis-of-anti-drug-antibodies-against-interferon-beta-and-natalizumab-in-multiple-sclerosis-patients-in-europe-a-descriptive-study-of-test-results
#5
Jenny Link, Ryan Ramanujam, Michael Auer, Malin Ryner, Signe Hässler, Delphine Bachelet, Cyprien Mbogning, Clemens Warnke, Dorothea Buck, Poul Erik Hyldgaard Jensen, Claudia Sievers, Kathleen Ingenhoven, Nicolas Fissolo, Raija Lindberg, Verena Grummel, Naoimh Donnellan, Manuel Comabella, Xavier Montalban, Bernd Kieseier, Per Soelberg Sørensen, Hans-Peter Hartung, Tobias Derfuss, Andy Lawton, Dan Sikkema, Marc Pallardy, Bernhard Hemmer, Florian Deisenhammer, Philippe Broët, Pierre Dönnes, Julie Davidson, Anna Fogdell-Hahn
Antibodies against biopharmaceuticals (anti-drug antibodies, ADA) have been a well-integrated part of the clinical care of multiple sclerosis (MS) in several European countries. ADA data generated in Europe during the more than 10 years of ADA monitoring in MS patients treated with interferon beta (IFNβ) and natalizumab have been pooled and characterized through collaboration within a European consortium. The aim of this study was to report on the clinical practice of ADA testing in Europe, considering the number of ADA tests performed and type of ADA assays used, and to determine the frequency of ADA testing against the different drug preparations in different countries...
2017: PloS One
https://www.readbyqxmd.com/read/27828855/the-cross-reactivity-of-binding-antibodies-with-different-interferon-beta-formulations-used-as-disease-modifying-drugs-in-multiple-sclerosis-patients
#6
Agnieszka Wencel-Warot, Slawomir Michalak, Marcin Warot, Alicja Kalinowska-Lyszczarz, Radoslaw Kazmierski
Interferon beta (IFNb) preparations are commonly used as first-line therapy in relapsing-remitting multiple sclerosis (RRMS). They are, however, characterized by limited efficacy, partly due to the formation of anti-IFNb antibodies in patients.In this pilot study, we assessed with the ELISA method the presence of the binding antibodies (BAbs) against interferon beta after 2 years of therapy with subcutaneous interferon beta 1a (Rebif) in 49 RRMS patients. Antibody levels were established again within 1 year after treatment withdrawal...
November 2016: Medicine (Baltimore)
https://www.readbyqxmd.com/read/27695075/risk-factors-for-poor-adherence-to-betaferon%C3%A2-treatment-in-patients-with-relapsing-remitting-multiple-sclerosis-or-clinically-isolated-syndrome
#7
Łukasz Jernas, Jacek Wencel, Andrzej Wiak, Marek Bieniek, Halina Bartosik-Psujek
INTRODUCTION: Adherence to treatment, including early treatment discontinuation, in patients with multiple sclerosis or clinically isolated syndrome can be affected by: treatment tolerability, route of drug administration, patient age, disease duration, comorbidities, medical care, and support from their caregivers. AIM: This study aimed to identify the risk factors for poor adherence to Betaferon® treatment, including early discontinuation and omitting doses. MATERIALS AND METHODS: 852 adult patients treated with Betaferon participated in this 24-month study...
2016: PloS One
https://www.readbyqxmd.com/read/27511182/the-11-year-long-term-follow-up-study-from-the-randomized-benefit-cis-trial
#8
RANDOMIZED CONTROLLED TRIAL
Ludwig Kappos, Gilles Edan, Mark S Freedman, Xavier Montalbán, Hans-Peter Hartung, Bernhard Hemmer, Edward J Fox, Frederik Barkhof, Sven Schippling, Andrea Schulze, Dirk Pleimes, Christoph Pohl, Rupert Sandbrink, Gustavo Suarez, Eva-Maria Wicklein
OBJECTIVE: To assess outcomes for patients treated with interferon beta-1b immediately after clinically isolated syndrome (CIS) or after a short delay. METHODS: Participants in BENEFIT (Betaferon/Betaseron in Newly Emerging MS for Initial Treatment) were randomly assigned to receive interferon beta-1b (early treatment) or placebo (delayed treatment). After conversion to clinically definite multiple sclerosis (CDMS) or 2 years, patients on placebo could switch to interferon beta-1b or another treatment...
September 6, 2016: Neurology
https://www.readbyqxmd.com/read/27112783/betaferon-in-chronic-viral-cardiomyopathy-bicc-trial-effects-of-interferon-%C3%AE-treatment-in-patients-with-chronic-viral-cardiomyopathy
#9
RANDOMIZED CONTROLLED TRIAL
Heinz-Peter Schultheiss, Cornelia Piper, Olaf Sowade, Finn Waagstein, Joachim-Friedrich Kapp, Karl Wegscheider, Georg Groetzbach, Matthias Pauschinger, Felicitas Escher, Eloisa Arbustini, Harald Siedentop, Uwe Kuehl
BACKGROUND: Chronic viral infections of the heart are considered one antecedent event leading to progressive dysfunction of the myocardium, often with an impaired prognosis due to a virus- or immune-mediated myocardial injury. Symptomatic treatment does not influence the viral cause of heart failure, and the effect of antiviral treatment has not been determined, yet. METHODS AND RESULTS: In this phase II study 143 patients with symptoms of heart failure and biopsy-based confirmation of the enterovirus (EV), adenovirus, and/or parvovirus B19 genomes in their myocardial tissue were randomly assigned to double-blind treatment, and received either placebo (n = 48) or 4 × 10(6) (n = 49) and 8 × 10(6) IU (n = 46) interferon beta-1b (IFN-β-1b) for 24 weeks, in addition to standard heart failure treatment...
September 2016: Clinical Research in Cardiology: Official Journal of the German Cardiac Society
https://www.readbyqxmd.com/read/26835734/immunogenicity-of-recombinant-human-interferon-beta-1b-in-immune-tolerant-transgenic-mice-corresponds-with-the-biophysical-characteristics-of-aggregates
#10
COMPARATIVE STUDY
Mohadeseh Haji Abdolvahab, Ahmad Fazeli, Andhyk Halim, Ahmad S Sediq, Mohammad Reza Fazeli, Huub Schellekens
Determining to what extent biophysical characteristics of aggregates affect immunogenicity of therapeutic interferon beta-1b. Three recombinant human interferon beta-1b (rhIFNβ-1b) samples with different levels of aggregates generated by copper oxidation, thermal stress, or left untreated, as well as Avonex(®) drug substance and Betaferon(®) drug product, were injected intraperitoneally in nontransgenic and interferon beta transgenic FVB/N mice 5 times per week for 3 weeks. Antibodies against interferon beta were measured using enzyme-linked immunosorbent assay...
April 2016: Journal of Interferon & Cytokine Research
https://www.readbyqxmd.com/read/26824268/an-albumin-free-formulation-for-escherichia-coli-derived-interferon-beta-1b-with-decreased-immunogenicity-in-immune-tolerant-mice
#11
Mohadeseh Haji Abdolvahab, Ahmad Fazeli, Mazda Radmalekshahi, M Reza Nejadnik, Mohammad Reza Fazeli, Huub Schellekens
Human serum albumin (HSA)-free formulation of Escherichia coli-derived human interferon beta (IFNβ-1b) with a high percentage of monomeric protein and low immunogenicity is developed and characterized in the current study. UV spectroscopy, fluorescence spectroscopy, dynamic light scattering, sodium dodecyl sulfate polyacrylamide gel electrophoresis, Western blotting, Micro-Flow Imaging, resonant mass measurement, size exclusion, and reversed-phase high performance liquid chromatographies were applied to assess the effect of excipients on the stability of IFNβ-1b to establish a HSA-free formulation...
March 2016: Journal of Interferon & Cytokine Research
https://www.readbyqxmd.com/read/26468869/increased-serum-brain-derived-neurotrophic-factor-in-multiple-sclerosis-patients-on-interferon-%C3%AE-and-its-impact-on-functional-abilities
#12
Masoud Mehrpour, Fahimeh H Akhoundi, Maryam Delgosha, Hosein Keyvani, Mohammad R Motamed, Behnam Sheibani, Alipasha Meysamie
OBJECTIVES: To investigate the potential role of disease-modifying therapies (DMTs) used to treat multiple sclerosis on inducing brain-derived neurotrophic factor (BDNF) production. METHODS: A total of 82 patients entered the study. Sixty (73%) patients were on DMTs (15 on Avonex, 13 on Rebif, 27 on Betaferon, 3 on Mitoxantrone, and 2 on IVIg), whereas 22 received no DMTs. The degree of neurological impairment was recorded using the expanded disability status scale (EDSS)...
October 2015: Neurologist
https://www.readbyqxmd.com/read/26458124/association-of-vitamin-d-levels-with-multiple-sclerosis-activity-and-progression-in-patients-receiving-interferon-beta-1b
#13
RANDOMIZED CONTROLLED TRIAL
Kathryn C Fitzgerald, Kassandra L Munger, Karl Köchert, Barry G W Arnason, Giancarlo Comi, Stuart Cook, Douglas S Goodin, Massimo Filippi, Hans-Peter Hartung, Douglas R Jeffery, Paul O'Connor, Gustavo Suarez, Rupert Sandbrink, Ludwig Kappos, Christoph Pohl, Alberto Ascherio
IMPORTANCE: Low serum 25-hydroxyvitamin D (25[OH]D) levels are associated with an increased risk of multiple sclerosis (MS) as well as with increased disease activity and rate of progression in clinically isolated syndromes and early MS. OBJECTIVE: To assess the association between 25(OH)D and disease course and prognosis in patients with relapsing-remitting MS treated with interferon beta-1b. DESIGN, SETTING, AND PARTICIPANTS: We conducted a prospective cohort study assessing 25(OH)D levels and subsequent MS disease course and progression characterized by magnetic resonance imaging (MRI) and clinical end points...
December 2015: JAMA Neurology
https://www.readbyqxmd.com/read/26453645/no-association-of-multiple-sclerosis-activity-and-progression-with-ebv-or-tobacco-use-in-benefit
#14
RANDOMIZED CONTROLLED TRIAL
Kassandra L Munger, Kathryn C Fitzgerald, Mark S Freedman, Hans-Peter Hartung, David H Miller, Xavier Montalbán, Gilles Edan, Frederik Barkhof, Gustavo Suarez, Ernst-Wilhelm Radue, Rupert Sandbrink, Ludwig Kappos, Christoph Pohl, Alberto Ascherio
OBJECTIVE: To evaluate whether Epstein-Barr virus (EBV) immunoglobulin G (IgG) antibody levels or tobacco use were associated with conversion to multiple sclerosis (MS) or MS progression/activity in patients presenting with clinically isolated syndrome (CIS). METHODS: In this prospective, longitudinal study, we measured EBV IgG antibody and cotinine (biomarker of tobacco use) levels at up to 4 time points (baseline, months 6, 12, and 24) among 468 participants with CIS enrolled in the BENEFIT (Betaferon/Betaseron in Newly Emerging Multiple Sclerosis for Initial Treatment) clinical trial...
November 10, 2015: Neurology
https://www.readbyqxmd.com/read/26436079/preliminary-study-on-patients-located-at-the-kashani-isfahan-hospital-with-multiple-sclerosis-between-the-years-2011-and-2013
#15
Zahra Tolou-Ghamari, Fereshteh Ashtari, Vahid Shaygannejad, Abbas-Ali Palizban
BACKGROUND: Multiple sclerosis (MS) is a multifactorial disease that could result from demyelination of the myelin sheath. The aim of this study is to investigate the demographic features and rank the immunomodulating drugs in patients with MS. MATERIALS AND METHODS: This study was conducted in the MS clinic of the Isfahan Kashani Hospital, from 22 May, 2011 to 18 March, 2013. The data analyses (n = 1067) were divided into two periods: (1) 2011/05/22 to 2012/03/18 denoted as P1 and (2) 2012/04/02 to 2013/03/18 denoted as P2...
2015: Advanced Biomedical Research
https://www.readbyqxmd.com/read/26346786/emerging-tumefactive-ms-after-switching-therapy-from-interferon-beta-to-fingolimod-a-case-report
#16
M H Harirchian, A Taalimi, B Siroos
We describe a case of tumefactive multiple sclerosis, based on characteristic imaging features and excluding alternative diagnoses, presented with relapse 18 weeks after switching betaferon to fingolimod. Recent reported cases of this paradoxical demyelinating reaction in a setting of fingolimod-related immune system alterations seem to be something more than an accidental event. Immune cell shifting underlying a genetic susceptibility factor has been suggested to participate in this disastrous adverse effect...
September 2015: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/26268445/development-of-interferon-beta-neutralising-antibodies-in-multiple-sclerosis-a-systematic-review-and-meta-analysis
#17
REVIEW
Karthik Govindappa, Jean Sathish, Kevin Park, Jamie Kirkham, Munir Pirmohamed
PURPOSE: Interferon beta (IFN-β) is the drug of choice for treatment of relapsing forms of multiple sclerosis and is known to reduce the frequency and severity of relapses. This systematic review determines the occurrence of neutralising antibodies (NAbs) against different formulations of IFN-β: IFN-β-1a Avonex™, IFN-β-1a Rebif™ and IFN-β-1b Betaferon/Betaseron™. METHODS: The databases used in the review included MEDLINE Ovid (from 1950 to March 2015), Embase Ovid (from 1980 to March 2015), CENTRAL on The Cochrane Library (2011, Issue 4) and ClinicalTrials...
November 2015: European Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/26214805/adherence-to-disease-modifying-drugs-among-patients-with-multiple-sclerosis-in-germany-a-retrospective-cohort-study
#18
Kerstin Hansen, Katrin Schüssel, Marita Kieble, Johanna Werning, Martin Schulz, Robert Friis, Dieter Pöhlau, Norbert Schmitz, Joachim Kugler
BACKGROUND: Long-term therapies such as disease modifying therapy for Multiple Sclerosis (MS) demand high levels of medication adherence in order to reach acceptable outcomes. The objective of this study was to describe adherence to four disease modifying drugs (DMDs) among statutorily insured patients within two years following treatment initiation. These drugs were interferon beta-1a i.m. (Avonex), interferon beta-1a s.c. (Rebif), interferon beta-1b s.c. (Betaferon) and glatiramer acetate s...
2015: PloS One
https://www.readbyqxmd.com/read/25907350/therapeutic-effect-of-avonex-rebif-and-betaferon-on-quality-of-life-in-multiple-sclerosis
#19
RANDOMIZED CONTROLLED TRIAL
Naghmeh Mokhber, Amir Azarpazhooh, Elias Orouji, Bita Khorram, Morteza Modares Gharavi, Sorayya Kakhi, Hoda Khallaghi, Mahmoud Reza Azarpazhooh
AIMS: The aim of this study was to evaluate the effect of various disease-modifying therapies (DMT) on quality of life in multiple sclerosis (MS). METHODS: This was a three-arm parallel study with balanced randomization in which 90 newly diagnosed, definite MS subjects referred to Ghaem Medical Center, Mashhad, Iran were enrolled between 2006 and 2009. Patients were randomly allocated into three DMT groups: Avonex, Rebif and Betaferon. Health-related quality of life was assessed in MS patients at baseline and 12 months after treatment with DMT using the MS Quality of Life-54 questionnaire...
October 2015: Psychiatry and Clinical Neurosciences
https://www.readbyqxmd.com/read/25543089/antibody-dissociation-rates-are-predictive-of-neutralizing-antibody-nab-course-a-comparison-of-interferon-beta-1b-treated-multiple-sclerosis-ms-patients-with-transient-versus-sustained-nabs
#20
RANDOMIZED CONTROLLED TRIAL
Ebrima Gibbs, Mohammad Ehsanul Karim, Joel Oger
A proportion of multiple sclerosis (MS) patients treated with interferon-β (IFNβ) develop neutralizing antibodies (NAbs), which can reduce therapeutic efficacy. In the Betaseron/Betaferon in Newly Emerging MS for Initial Treatment (BENEFIT) study, 88/277 patients developed NAbs, 48 having transient positivity and 29 having sustained positivity. This study aimed to investigate the antibody binding characteristics of serial sera in a subset of these two patient groups. Using Biacore™, a surface plasmon resonance-based technology that monitors biomolecular interactions in real time, we immobilized pure IFNβ-1b and analyzed antibody binding responses and dissociation rates of these sera...
March 2015: Clinical Immunology: the Official Journal of the Clinical Immunology Society
keyword
keyword
81806
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"